Oral Ribavirin for RSV Pneumonia in Adults

Introduction to Treatment Recommendations

The American College of Physicians and the Infectious Diseases Society of America recommend that oral ribavirin should not be used routinely in immunocompetent adults with RSV pneumonia, but should be strongly considered in moderately to severely immunocompromised patients, particularly hematopoietic stem cell transplant recipients, solid organ transplant recipients, and those on active chemotherapy 1, 2, 3

The evidence clearly shows no established efficacy for ribavirin in treating RSV pneumonia in immunocompetent adults, with a D-I recommendation from the 2003 Clinical Infectious Diseases guidelines 1, 2

The European Conference on Infections in Leukemia (ECIL-4) guidelines recommend treating upper respiratory tract infection in HSCT patients undergoing transplant or with risk factors for progression with aerosolized or systemic ribavirin and IVIG (BII recommendation) 4, 5, 6
The ECIL-4 guidelines also recommend treating lower respiratory tract infection in allogeneic HSCT patients with aerosolized or systemic ribavirin, which may be combined with IVIG or anti-RSV-enriched antibody preparations (BII-BIII recommendations) 4, 5
Oral ribavirin is an effective and easier-to-administer alternative to aerosolized ribavirin for HSCT patients with RSV infection, with a recommended dosing schedule of 600-800 mg twice daily 4, 5, 3

Day	Dosing Schedule
1	600 mg loading dose, then 200 mg every 8 hours [3]
2	400 mg every 8 hours [3]
3 onward	Increase to maximum 10 mg/kg body weight every 8 hours [6]

Adjust for renal impairment: Maximum 200 mg every 8 hours for creatinine clearance 30-50 mL/min 6, 3

Monitor patients on oral ribavirin for hemolytic anemia, abnormal liver function tests, declining renal function, and other adverse effects 4, 5, 3
For aerosolized ribavirin, apply appropriate precautions to avoid environmental exposure, particularly for pregnant healthcare workers due to teratogenic effects, and monitor for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function 4, 5, 3

Do not use ribavirin routinely in previously healthy adults with RSV pneumonia, as the evidence does not support benefit and exposes patients to unnecessary risks and costs 1, 2, 3
Do not use palivizumab for treatment, as it has no therapeutic benefit for established RSV infection and is only approved for prophylaxis 3
Do not delay treatment in immunocompromised patients, as early initiation is critical for reducing mortality 4, 5, 6
Do not use three or more antiviral drugs simultaneously 7

For hematopoietic stem cell transplant recipients, solid organ transplant recipients, or patients receiving active chemotherapy, aerosolized ribavirin should be strongly considered, with a dosing regimen of 2 g for 2 hours every 8 hours OR 6 g over 18 hours daily for 7-10 days, as recommended by the Infectious Diseases Society of America 8, 9, 10
Oral ribavirin 600-800 mg twice daily is an effective alternative to aerosolized therapy for immunocompromised patients, with dosing adjustments for renal impairment, as suggested by the Clinical Infectious Diseases guidelines 8

For allogeneic HSCT patients with RSV pneumonia, combining ribavirin with IVIG (500 mg/kg every other day) or anti-RSV-enriched antibody preparations is recommended, with improved outcomes in prospective trials, as reported by the Clinical Infectious Diseases journal 8, 9, 10

Patients on aerosolized ribavirin should be monitored for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function, with strict precautions to avoid environmental exposure, as advised by the Clinical Infectious Diseases guidelines 9, 10
Patients on oral/systemic ribavirin should be monitored for hemolytic anemia, abnormal liver function tests, and declining renal function, as recommended by the Clinical Infectious Diseases journal 8, 9, 10

For immunocompromised patients, defer conditioning therapy or chemotherapy until RSV infection is resolved, as suggested by the Infectious Diseases Society of America 8, 9